No Data
Rezolute Is Maintained at Buy by BTIG
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating
Maxim Group analyst Jason McCarthy maintains $Rezolute(RZLT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 23.4% and a total average return of -23.4% over the
Rezolute's Drug Pipeline Progress and FDA Hold Lift Propel Buy Rating and Increased Price Target
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $7 to $15
On Sep 10, major Wall Street analysts update their ratings for $Rezolute(RZLT.US)$, with price targets ranging from $7 to $15.BTIG analyst Julian Harrison maintains with a buy rating, and adjusts
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
Rezolute Analyst Ratings